News & Research - HBM Partners AG

NEWS & RESEARCH

Portfolio News

HBM in the News

HBM M&A Report

iTeos Presents New Data for Anti-TIGIT Antibody, EOS-448/GSK4428859A, at the AACR Annual Meeting 2022 (121 KB)
08.04.2022
Download
Galecto Completes Enrollment in Phase 1b/2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis (27 KB)
29.03.2022
Download
Aculys Pharma Closes US$24 Million Series B Financing Joined by Domestic and Foreign Investors (509 KB)
28.03.2022
Download
Pharmacy Marketplace 1000Farmacie Closes $15M Series A Financing Round Led by P101 SGR and HBM Healthcare Investments (241 KB)
7.2.2022
Download
NEURELIS Signs Exclusive Licensing Agreement with ACULYS PHARMA for the Development and Commercialization of VALTOCO® (DIAZEPAM NASAL SPRAY) in Japan and the Asia-Pacific Region (163 KB)
25.1.2022
Download
Significant Investment Accelerates Freenome's Multiomics Platform for the Early Detection of Cancer (29 KB)
11.1.2022
Download
Dren Bio Announces Research Collaboration and License Agreement with Pfizer to Discover and Advance Multiple Therapeutic Antibodies Using its Targeted Myeloid Engager and Phagocytosis Platform for the Treatment of Cancer (131 KB)
11.1.2022
Download
AMGEN AND ARRAKIS THERAPEUTICS ANNOUNCE MULTI-TARGET COLLABORATION TO IDENTIFY NOVEL RNA DEGRADER SMALL MOLECULE THERAPEUTICS (88 KB)
11.1.2022
Download
SWIXX SELECTED AS GILEAD’S BALTIC PARTNER (137 KB)
16.12.2021
Download
SWIXX SIGNS EXCLUSIVE DISTRIBUTION AGREEMENT WITH SANOFI FOR FOURTEEN CEE COUNTRIES (229 KB)
13.12.2021
Download

<3 4 567 8 >

„Ungebremste Innovationskraft" (628 KB)
1.5.2019
Download Read more
Unbridled Capacity for Innovation (101 KB)
1.5.2019
Download Read more
Investieren in Listed Private Equity - mehr als eine Alternative (2023 KB)
23.1.2019
Download Read more
Investing in listed private equity – more than just an alternative (197 KB)
23.1.2019
Download Read more
Kleine Hersteller, grosses Potenzial (1007 KB)
1.1.2019
Download Read more
Investieren in den Gesundheitssektor – Chancen für den Anleger (487 KB)
4.11.2018
Download Read more
A Biotechnology Bonanza (397 KB)
1.10.2018
Download Read more
Andreas Wicki, CEO HBM Healthcare Investments, im Interview (345 KB)
13.8.18
Download Read more
Die Reize der Swiss Biotechs (581 KB)
25.7.2018
Download Read more
Der Kampf gegen das Vergessen (561 KB)
4.6.2018
Download Read more
Die Zuversicht für den Biotech-Sektor wächst (328 KB)
18.11.2017
Download Read more
Novartis setzt auf Nuklearmedizin (106 KB)
31.10.2017
Download Read more
Novartis's neue Wette im Krebsgeschäft (1502 KB)
31.10.2017
Download Read more
Trends und Chancen für den Anleger (840 KB)
1.9.2017
Download Read more
Strong Vital Signs in Biotech Innovation (4732 KB)
1.9.2017
Download Read more
Fokus auf Innovation (118 KB)
1.9.2017
Download Read more
Wie Anleger erfolgreich in Biotech investieren (535 KB)
27.5.2017
Download Read more
Trump und Big Pharma sind eine Hassliebe (166 KB)
4.2.2017
Download Read more
Fondsspezialitäten und ihre Macher (138 KB)
1.2.2017
Download Read more
Wie Biotech-Aktien auf Donald Trump reagieren (683 KB)
26.1.2017
Download Read more

<1 234 >

HBM Biopharma M&A Report 2022

HBM Biopharma M&A Database 2005-2022 (Excel)

Credits

Sitemap

iTeos Presents New Data for Anti-TIGIT Antibody, EOS-448/GSK4428859A, at the AACR Annual Meeting 2022 (121 KB)

Galecto Completes Enrollment in Phase 1b/2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis (27 KB)

Aculys Pharma Closes US$24 Million Series B Financing Joined by Domestic and Foreign Investors (509 KB)

Pharmacy Marketplace 1000Farmacie Closes $15M Series A Financing Round Led by P101 SGR and HBM Healthcare Investments (241 KB)

NEURELIS Signs Exclusive Licensing Agreement with ACULYS PHARMA for the Development and Commercialization of VALTOCO® (DIAZEPAM NASAL SPRAY) in Japan and the Asia-Pacific Region (163 KB)

Significant Investment Accelerates Freenome's Multiomics Platform for the Early Detection of Cancer (29 KB)

Dren Bio Announces Research Collaboration and License Agreement with Pfizer to Discover and Advance Multiple Therapeutic Antibodies Using its Targeted Myeloid Engager and Phagocytosis Platform for the Treatment of Cancer (131 KB)

AMGEN AND ARRAKIS THERAPEUTICS ANNOUNCE MULTI-TARGET COLLABORATION TO IDENTIFY NOVEL RNA DEGRADER SMALL MOLECULE THERAPEUTICS (88 KB)

SWIXX SELECTED AS GILEAD’S BALTIC PARTNER (137 KB)

SWIXX SIGNS EXCLUSIVE DISTRIBUTION AGREEMENT WITH SANOFI FOR FOURTEEN CEE COUNTRIES (229 KB)

„Ungebremste Innovationskraft" (628 KB)

Unbridled Capacity for Innovation (101 KB)

Investieren in Listed Private Equity - mehr als eine Alternative (2023 KB)

Investing in listed private equity – more than just an alternative (197 KB)

Kleine Hersteller, grosses Potenzial (1007 KB)

Investieren in den Gesundheitssektor – Chancen für den Anleger (487 KB)

A Biotechnology Bonanza (397 KB)

Andreas Wicki, CEO HBM Healthcare Investments, im Interview (345 KB)

Die Reize der Swiss Biotechs (581 KB)

Der Kampf gegen das Vergessen (561 KB)

Die Zuversicht für den Biotech-Sektor wächst (328 KB)

Novartis setzt auf Nuklearmedizin (106 KB)

Novartis's neue Wette im Krebsgeschäft (1502 KB)

Trends und Chancen für den Anleger (840 KB)

Strong Vital Signs in Biotech Innovation (4732 KB)

Fokus auf Innovation (118 KB)

Wie Anleger erfolgreich in Biotech investieren (535 KB)

Trump und Big Pharma sind eine Hassliebe (166 KB)

Fondsspezialitäten und ihre Macher (138 KB)

Wie Biotech-Aktien auf Donald Trump reagieren (683 KB)